The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback